🇺🇸 FDA
Patent

US 8012490

Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents

granted A61KA61K2039/5256A61K2039/53

Quick answer

US patent 8012490 (Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Sep 01 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Sep 06 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 01 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/5256, A61K2039/53, A61P, A61P37/04